SKYE
Skye Bioscience, Inc. Common Stock
NASDAQ: SKYE · HEALTHCARE · BIOTECHNOLOGY
$0.88
-1.71% today
Updated 2026-04-30
Market cap
$22.94M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.30
Dividend yield
—
52W range
$1 – $6
Volume
0.6M
Skye Bioscience, Inc. Common Stock (SKYE) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $42884.00 | $145694.00 | $348347.00 | $3.51M | $323363.00 | $557218.00 | $1.96M | $2.00M | $2.67M | $9.86M | $9.11M | $11.94M | $72.76M |
| Cash & equivalents | $26404.00 | $52186.00 | $207330.00 | $3.22M | $64820.00 | $259955.00 | $1.85M | $1.83M | $2.47M | $8.98M | $1.24M | $1.26M | $68.42M |
| Current assets | $38348.00 | $106134.00 | $308399.00 | $3.45M | $279489.00 | $555811.00 | $1.95M | $1.99M | $2.66M | $9.61M | $8.94M | $11.65M | $70.83M |
| Total liabilities | $4325.00 | $182153.00 | $801895.00 | $3.04M | $1.77M | $1.36M | $17.52M | $1.45M | $2.22M | $3.99M | $12.12M | $14.07M | $4.61M |
| Current liabilities | $4325.00 | $182153.00 | $801090.00 | $581860.00 | $661958.00 | $805974.00 | $15.94M | $970818.00 | $787199.00 | $3.91M | $12.12M | $13.90M | $4.34M |
| Long-term debt | — | — | — | — | — | — | $1.36M | $387070.00 | $1.43M | — | — | — | — |
| Shareholder equity | $38559.00 | $-182153.00 | $-453548.00 | $470996.00 | $-1.45M | $-800078.00 | $-15.56M | $548058.00 | $450786.00 | $5.86M | $-3.01M | $-2.13M | $68.15M |
| Retained earnings | $459.00 | $-183153.00 | $-2.92M | $-7.76M | $-10.94M | $-14.03M | $-33.23M | $-32.17M | $-38.73M | $-47.26M | $-66.74M | $-104.38M | $-130.95M |
| Accounts receivable | $11944.00 | $25338.00 | — | — | — | — | — | — | — | — | $74121.00 | $158242.00 | $5065.00 |
| Inventory | — | $13019.00 | — | — | — | — | — | — | — | — | $7.21M | $125784.00 | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | — |